The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
 
Marcelo Raul Bonomi
Research Funding - EpicentRx (Inst)
 
David Sher
No Relationships to Disclose
 
Dukagjin Blakaj
No Relationships to Disclose
 
Rafi Kabarriti
No Relationships to Disclose
 
Kyle Colvett
No Relationships to Disclose
 
Bryan Oronsky
Employment - EpicentRx
Leadership - EpicentRx; EpicentRx (I)
Stock and Other Ownership Interests - EpicentRx
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor of several technologies under EpicentRx. Inc.
 
Stephen T. Sonis
Employment - Biomodels; Primary Endpoint Solutions
Leadership - Biomodels; Immunity Health; Primary Endpoint Solutions; Primary Endpoint Solutions
Stock and Other Ownership Interests - BioInsight Diagnostics; Biomodels; Immunity Health; Inform Genomics
Consulting or Advisory Role - Biomodels (Inst); Primary Endpoint Solutions (Inst)
Research Funding - Biomodels (Inst); Primary Endpoint Solutions (Inst)
Patents, Royalties, Other Intellectual Property - Predictive genomics (Inst); Raman spectropscopy
 
James A. Bianco
Employment - Prothex Pharma
Stock and Other Ownership Interests - Prothex Pharma; Prothex Pharma
Travel, Accommodations, Expenses - Prothex Pharma; Prothex Pharma; Prothex Pharma